Newsletter
Contact
Careers
Calendar
RFP
Français
myGAVI
Donate
Home
About the Alliance
Learn more about GAVI
GAVI's mission
What we do
GAVI's impact
Challenges and opportunities
Healthy girls, healthy women
Gender and immunisation
Why invest in GAVI?
Advocates
GAVI's strategy
Value of vaccination
GAVI's partnership model
GAVI's business model
Global health and development
Governing GAVI
GAVI Board
GAVI Secretariat
GAVI Internal Audit
Programmatic and Finance Policies
Corporate Policies
Types of support
What GAVI offers and how it works
Apply for support
New and underused vaccines support
Human papillomavirus vaccine
Injection safety support
Measles vaccine
Meningitis A vaccine
Pentavalent vaccine
Pneumococcal vaccine
Measles-Rubella vaccine
Rotavirus vaccine
Yellow fever vaccine
Immunisation services support
Health Systems Funding Platform
Health system strengthening
Civil society organisation
Country hub
Afghanistan
Albania
Angola
Armenia
Azerbaijan
Bangladesh
Benin
Bhutan
Bolivia
Bosnia & Herzegovina
Burkina Faso
Burundi
Cambodia
Cameroon
Central African Republic (the)
Chad
China
Comoros
Congo
Congo, DR
Côte d’Ivoire
Cuba
Djibouti
Eritrea
Ethiopia
Gambia
Georgia
Ghana
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
India
Indonesia
Kenya
Kiribati
Korea, DPR
Kyrgyzstan
Lao PDR
Lesotho
Liberia
Madagascar
Malawi
Mali
Mauritania
Moldova
Mongolia
Mozambique
Myanmar
Nepal
Nicaragua
Niger
Nigeria
Pakistan
Papua New Guinea
Rwanda
Sao Tome and Principe
Senegal
Sierra Leone
Solomon Islands
Somalia
South Sudan
Sri Lanka
Sudan
Tajikistan
Tanzania, UR
Timor Leste
Togo
Turkmenistan
Uganda
Ukraine
Uzbekistan
Vietnam
Yemen
Zambia
Zimbabwe
Funding & finance
Long-term financial commitments
How GAVI is funded
Key figures: donor contributions & pledges
Donor profiles
Financial reports
GAVI Matching Fund
How it works
Partners
International Finance Facility for Immunisation
Pneumococcal AMC
Results & evidence
Measuring & evaluating performance
Goal-level indicators
Mission indicators
Vaccine goal indicators
Health systems goal indicators
Financing goal indicators
Market-shaping goal indicators
Countries approved for support
Disbursements by country
GAVI's evaluation studies
GAVI first evaluation report
GAVI second evaluation report
GAVI support to CSO evaluation
GAVI-Government of China Hepatitis B vaccination programme
Gender Policy evaluation
IFFIm evaluation
Pneumococcal AMC process and design
Other studies
GAVI Progress reports
Library & news
Search by topic, country and programme
News
Press releases
Statements
Return on investment stories
GAVI features
Eyewitness
GAVI blogs
Audio-visual
Board & committee minutes
GAVI documents
Country documents
Evaluations
Financial reports
Guidelines and forms
Policies
Strategy
Supply and procurement
Publications
Events
You are here:
Library
Audio-visual
Audio-visual
Galleries
Galleries
Laos' efforts to stop rubella and measles for good
Laos' efforts to stop rubella and measles for good
in page functions
In November 2011, Laos is introducing rubella vaccine for the first time. During a two-phase campaign, Laos plans to immunise more than three million young people with the combined vaccine for measles and rubella ("MR" vaccine), offering protection against two preventable diseases.
16 November 2011
The Measles Initiative/C. McNab/2011
Students study mathematics at Kang village school in southern Laos while health workers set up a vaccination post outside their classroom in November 2011, part of a campaign to protect them from measles and rubella. By preventing death and disease, immunisation gives children the best possible start in life.
The Measles Initiative/C. McNab/2011
A young girl closes her eyes while receiving immunisation against measles and rubella at a village school in Pakse District, southern Laos, in November 2011. Introducing rubella vaccine into Laos, a month-long campaign will immunise three million youngsters aged between 9 months and 19 years from measles and rubella.
The Measles Initiative/C. McNab/2011
Girls approaching child bearing age must be reached with the MR vaccine, as rubella infection in pregnant women can cause severe birth disorders in newborns. These include heart disease, blindness and deafness. This girl receives her vaccine at Kang Village School in Pakse District, southern Laos.
The Measles Initiative/C. McNab/2011
Rubella vaccines are usually delivered in a combined measles-rubella vaccine, such as this one set for use in Laos during a national measles rubella campaign in November 2011. The Laos Government secured a donation of more than 3 million doses of the Measles and Rubella or "MR" vaccine for its nationwide campaign.
The Measles Initiative/C. McNab/2011
Rubella vaccines are usually delivered in a combined measles-rubella vaccine, such as this one set for use in Laos during a national measles rubella campaign in November 2011.
The Measles Initiative/C. McNab/2011
"A recent survey in Laos showed that 35% of girls aged 15-19 had no immunity against rubella", explains Dr. Phounphenjhack Kongxay, Lao's Deputy Manager of the national immunization program. "It was very important to add rubella vaccine to protect women and their newborns." Here Dr Kongxay immunizes a girl in Don Thalat school in the Champasack District of Southern Laos.
The Measles Initiative/C. McNab/2011
"When I heard we were introducing combined measles and rubella vaccine I was very happy," says Mrs Suphaphane, the immunisation programme manager for Pakse district in southern Laos. "I have seen the tragedy of congenital rubella syndrome and it is a relief we can now prevent it. With this MR vaccine, we can protect the people of Laos against two diseases with a single injection."
The Measles Initiative/C. McNab/2011
Dr. Phounphenjhack Kongxay, Lao's Deputy Manager of the national immunization programme and WHO's Rajesh Bhaskar check students’ fingers as they head home from school in Paksong District high on the Bolaven Plateau in November 2011. Young people are marked with purple ink on their left pinky fingers following immunisation so that monitors can quickly tell if they have been reached by the campaign.
The Measles Initiative/C. McNab/2011
The Laos Ministry of Health is working to improve surveillance for rubella so that cases can be laboratory confirmed. Blood samples from people with fever and rash - the markers for both measles and rubella - are sent from the field for testing to the Laos National Center for Laboratory and Epidemiology in Laos' capital Vientiane.
The Measles Initiative/C. McNab/2011
A young woman receives immunisation against measles and rubella during an immunisation campaign in Laos, November 2011. The rubella virus can lead to miscarriage, still births, or birth defects when passed from mother to child during pregnancy. An estimated 90,000 birth defects, known collectively as congenital rubella syndrome (CRS), happen every year in the world’s poorest countries.
The Measles Initiative/C. McNab/2011
Laotian children pose for the camera in Laos, November 2011. The south-east Asian country conducted an immunisation campaign the same month to protect against measles and immunisation in November 2011.
Search keywords
Laos
rubella
measles
modal window here